​

Funding Round

Series A - Ceptur Therapeutics

Series A - Ceptur Therapeutics

Investment Firm

Overview

Revolutionizing gene silencing by developing targeted oligonucleotide therapeutics based on U1 Adaptor technology

Announced Date

Jan 19, 2022

Closed on Date

Feb 14, 2022

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

Qiming Venture Partners

Qiming Venture Partners

Qiming Venture Partners is a early_stage_venture and late_stage_venture and private_equity and seed firm.

venBio Partners

venBio Partners

venBio Partners is a early_stage_venture and late_stage_venture and post_ipo and seed and venture firm.

Participant Investors

5

Investor Name
Participant InvestorBoxer Capital
Participant InvestorPerceptive Advisors
Participant InvestorvenBio Partners
Participant InvestorBristol-Myers Squibb
Participant InvestorQiming Venture Partners

Round Details and Background

Ceptur Therapeutics raised $75000000 on 2022-01-19 in Series A

Revolutionizing gene silencing by developing targeted oligonucleotide therapeutics based on U1 Adaptor technology

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Aug 13, 2020
Venture Round - Ceptur Therapeutics
1-6.2M
Jan 19, 2022
Series A - Ceptur Therapeutics
8-75.0M

Recent Activity

There is no recent news or activity for this profile.